Table 1.
Variable | Category | Crude model | Plus age | Plus sex | Plus boosted | Plus weeks since vaccination | Plus prior COVID-19 | Plus weeks since symptom onset | Plus calendar time (weeks) |
---|---|---|---|---|---|---|---|---|---|
Omicron variant | BA.1 [ref] | – | – | – | – | – | – | – | – |
BA.2 | 1.86 (1.59,2.18) | 1.93 (1.64,2.28) | 1.94 (1.64,2.29) | 1.97 (1.66,2.33) | 1.91 (1.58,2.29) | 1.92 (1.59,2.30) | 1.70 (1.40,2.06) | 1.54 (1.16,2.06) | |
Age | 18–24 [ref] | – | – | – | – | – | – | – | |
25–34 | 1.22 (0.80,1.84) | 1.26 (0.83,1.91) | 1.26 (0.83,1.92) | 1.26 (0.83,1.91) | 1.27 (0.83,1.93) | 1.13 (0.73,1.74) | 1.13 (0.74,1.75) | ||
35–44 | 1.64 (1.09,2.46) | 1.70 (1.14,2.56) | 1.73 (1.15,2.60) | 1.71 (1.14,2.57) | 1.72 (1.14,2.58) | 1.63 (1.07,2.49) | 1.65 (1.08,2.51) | ||
45–54 | 2.07 (1.39,3.10) | 2.19 (1.47,3.29) | 2.25 (1.49,3.38) | 2.21 (1.47,3.33) | 2.20 (1.46,3.32) | 2.09 (1.37,3.19) | 2.12 (1.39,3.25) | ||
55–64 | 2.12 (1.42,3.16) | 2.30 (1.54,3.43) | 2.36 (1.57,3.55) | 2.31 (1.54,3.48) | 2.32 (1.54,3.48) | 2.24 (1.47,3.41) | 2.28 (1.49,3.49) | ||
65–74 | 1.24 (0.81,1.88) | 1.39 (0.91,2.11) | 1.43 (0.93,2.19) | 1.39 (0.90,2.14) | 1.37 (0.89,2.11) | 1.33 (0.85,2.08) | 1.36 (0.86,2.13) | ||
Sex | Female [ref] | – | – | – | – | – | – | ||
Male | 0.57 (0.48,0.67) | 0.57 (0.48,0.68) | 0.57 (0.48,0.68) | 0.57 (0.48,0.68) | 0.62 (0.52,0.73) | 0.62 (0.52,0.73) | |||
Boosted (Yes) | No [ref] | – | – | – | – | – | |||
Yes | 0.90 (0.71,1.15) | 0.97 (0.72,1.31) | 0.96 (0.71,1.29) | 0.92 (0.67,1.27) | 0.88 (0.62,1.24) | ||||
Weeks since last vaccination | 1.00 (0.99,1.01) | 1.00 (0.99,1.01) | 1.01 (0.99,1.02) | 1.00 (0.99,1.02) | |||||
Prior COVID-19 (28+ days ago) |
No [ref] | – | – | – | |||||
Yes | 0.64 (0.47,0.87) | 0.92 (0.65,1.30) | 0.92 (0.65,1.29) | ||||||
Weeks since symptom onset | 0.81 (0.66,0.98) | 0.81 (0.67,0.98) | |||||||
Calendar time (weeks since 1 Jan) | 1.02 (0.98,1.05) |
Each column shows the addition of one covariate to the model. Odds ratios and 95% confidence intervals are shown. BA.2 infection (vs BA.1) is associated with increased risk of reduced ability to carry out day-to-day activities. This effect is robust to adjustment. Vaccine booster status was not associated with a change in ability to carry out daily activities.